secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0001664710-24-000102
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros halts two high-dose arms of Phase 2 PAH trial after pericardial effusion
------------------------------------------------------------------------------

- Voluntarily halted dosing in 3.0 mg/kg and 4.5 mg/kg cibotercept arms in ongoing TROPOS trial.
- Decision based on unanticipated pericardial effusion adverse events; safety review triggered.
- 1.5 mg/kg treatment arm continues dosing after DMC and internal risk-benefit assessment.
- Topline data from all treatment arms still expected in Q2 2025; FDA and other regulators notified.
- CEO Jasbir Seehra stated patient safety is top priority; Company investigating findings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000102/0001664710-24-000102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000102/kros-20241212.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer